简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
11
2026-06
VOLUNTARY ANNOUNCEMENT LICENSING OF DULAGLUTIDE INJECTION IN THE U.S.
03
2026-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
29
2026-05
VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR TWO DENOSUMAB BIOSIMILARS IN THE U.S.
27
2026-05
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 22 JUNE 2026 (APPLICABLE TO HOLDERS OF H SHARES)
27
2026-05
NOTICE OF ANNUAL GENERAL MEETING
27
2026-05
(1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) RE-APPOINTMENT OF AUDITOR (5) REMUNERATION OF DIRECTORS (6) REMUNERATION OF SUPERVISORS (7) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES (8) GEN
26
2026-05
VOLUNTARY ANNOUNCEMENT BOLUOJIA (DENOSUMAB INJECTION) NEWLY APPROVED IN CHINA FOR TREATING BONE METASTASES FROM SOLID TUMORS AND MULTIPLE MYELOMA
13
2026-05
VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE
07
2026-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
29
2026-04
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
1
2
3
4
5
Follow me
鲁公网安备37069102000284